GSK

1,398

+2.61%↑

INDV

835

+1.46%↑

GSK

1,398

+2.61%↑

INDV

835

+1.46%↑

GSK

1,398

+2.61%↑

INDV

835

+1.46%↑

GSK

1,398

+2.61%↑

INDV

835

+1.46%↑

GSK

1,398

+2.61%↑

INDV

835

+1.46%↑

Search

AstraZeneca PLC

Suletud

SektorTervishoid

10,328 1.65

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

10160

Max

10370

Põhinäitajad

By Trading Economics

Sissetulek

1.3B

2.9B

Müük

-1.3B

14B

P/E

Sektori keskmine

27.219

56.602

Aktsiakasum

148.337

Dividenditootlus

2.4

Kasumimarginaal

21.46

Töötajad

94,300

EBITDA

648M

5.1B

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+33.11% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

2.40%

2.45%

Järgmine tulemuste avaldamine

29. juuli 2025

Järgmine aktsia dividendi kuupäev (ex-date)

7. aug 2025

Turustatistika

By TradingEconomics

Turukapital

-18B

164B

Eelmine avamishind

10326.35

Eelmine sulgemishind

10328

Uudiste sentiment

By Acuity

37%

63%

124 / 382 Pingereas Healthcare

AstraZeneca PLC Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

12. mai 2025, 09:36 UTC

Suurimad hinnamuutused turgudel

Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices

29. apr 2025, 10:14 UTC

Tulu

Correction to AstraZeneca Update

29. apr 2025, 09:15 UTC

Tulu

AstraZeneca Sales, Earnings Rise; Warns of Mounting Legal Challenges in China -- 2nd Update

29. apr 2025, 08:12 UTC

Tulu

AstraZeneca Sales, Earnings Rise; Warns of Mounting Legal Challenges in China -- Update

29. apr 2025, 06:32 UTC

Tulu

AstraZeneca Sales, Earnings Rise

24. märts 2025, 03:15 UTC

Suurimad hinnamuutused turgudel

Harbour BioMed Shares Soar on News of AstraZeneca Collaboration

17. märts 2025, 07:42 UTC

Omandamised, ülevõtmised, äriostud

AstraZeneca Buys Belgian EsoBiotec for Up to $1 Billion to Boost Cell-Therapy Portfolio

12. mai 2025, 12:07 UTC

Market Talk

Trump's Drug Price Cap Plan Is 'Alarming' for Pharma Sector -- Market Talk

12. mai 2025, 07:20 UTC

Market Talk

Pharma Shares Face Risks From Trump's Pricing Plans -- Market Talk

8. mai 2025, 15:20 UTC

Tulu

Trump Announces U.S.-U.K. Trade Deal. Most Tariffs Aren't Coming Down. -- Barrons.com

29. apr 2025, 13:09 UTC

Market Talk
Tulu

AstraZeneca's Oncology Miss Doesn't Dent Positive Outlook -- Market Talk

29. apr 2025, 08:04 UTC

Market Talk
Tulu

AstraZeneca's Results Provide a Mixed Picture -- Market Talk

29. apr 2025, 06:05 UTC

Tulu

AstraZeneca 1Q Core EPS $2.49

29. apr 2025, 06:04 UTC

Tulu

AstraZeneca 1Q Net Pft $2.92B

29. apr 2025, 06:02 UTC

Tulu

AstraZeneca: Committed to Further Invest and Grow in the U.S.

29. apr 2025, 06:00 UTC

Tulu

AstraZeneca 1Q Core EPS Consensus Was $2.27

29. apr 2025, 06:00 UTC

Tulu

AstraZeneca 1Q Revenue Consensus Was $13.80B

29. apr 2025, 06:00 UTC

Tulu

AstraZeneca Backs 2025 View

29. apr 2025, 06:00 UTC

Tulu

AstraZeneca PLC 1Q EPS $1.87

29. apr 2025, 06:00 UTC

Tulu

AstraZeneca PLC 1Q Rev $13.59B

29. apr 2025, 06:00 UTC

Tulu

AstraZeneca PLC 1Q Oper Pft $3.67B

29. apr 2025, 06:00 UTC

Tulu

AstraZeneca PLC 1Q Pretax Pft $3.4B

15. apr 2025, 09:55 UTC

Market Talk

U.S Pharma Import Probe Clouds Clarity for EU Companies -- Market Talk

9. apr 2025, 07:23 UTC

Market Talk

Pharma Stocks Tumble After Trump Floats Tariffs on Industry -- Market Talk

3. apr 2025, 08:41 UTC

Market Talk

Big Pharma Left Uncertain About U.S. Tariff Risk -- Market Talk

3. apr 2025, 08:36 UTC

Market Talk

U.K. Pharma to Have Some Share-Price Volatility But Long-Term Outlook Remains Intact -- Market Talk

3. apr 2025, 07:51 UTC

Market Talk

Big Pharma Stocks Rise After Exclusion From U.S. Tariffs -- Market Talk

31. märts 2025, 09:31 UTC

Kuumad aktsiad

Stocks to Watch Monday: Nvidia, Tesla, Robinhood, Tokyo Electron -- WSJ

17. märts 2025, 14:43 UTC

Market Talk

AstraZeneca's Latest Rare-Disease Drug Results Slightly Disappoint, Barclays Says -- Market Talk

17. märts 2025, 13:55 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

AstraZeneca's EsoBiotec Deal Seen as Logical -- Market Talk

Võrdlus sarnastega

Hinnamuutus

AstraZeneca PLC Prognoos

Hinnasiht

By TipRanks

33.11% tõus

12 kuu keskmine prognoos

Keskmine 13,340.17 GBX  33.11%

Kõrge 16,500 GBX

Madal 10,900 GBX

Põhineb 14 Wall Streeti analüütiku instrumendi AstraZeneca PLC 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

14 ratings

10

Osta

4

Hoia

0

Müü

Sentiment

By Acuity

124 / 382 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest AstraZeneca PLC

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.